AbbVie stock gains 2.25 percent before October earnings date

Published on 10/07/2026 at 16:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock traded at USD 272.68 on October 7, 2026, as the next report is listed for October 30. Q2 revenue reached USD 16.99 billion, up 10.2 percent year over year.

Redaktionsfoto des NYSE-Handelssaals mit Händlern und grünen Pharma-Aktiencharts auf Monitoren — AbbVie Inc. US00287Y1091 NYSE Handelssaal Editorial Fotografie Händler Pharma Aktiencharts grüne Kurven auf Monitoren, Illustration mit AI erstellt.

AbbVie Inc. (US00287Y1091) was trading at USD 272.68 on the NYSE on October 7, 2026, at 10:22 a.m. ET, up 2.25 percent from USD 266.69. The next earnings report is listed for October 30, 2026, giving the recent rally a clear near-term checkpoint.

October report sets the next test

According to StockHub, AbbVie is scheduled to report its next earnings on October 30, 2026. The date places the stock close to its yearly high, but the upcoming report will test whether the company can sustain the earnings momentum already reflected in the valuation.

AbbVie had reported second-quarter revenue of USD 16.99 billion, up 10.2 percent from the year-earlier period, while adjusted EPS reached USD 3.65 versus USD 2.97 a year earlier, according to MarketBeat in its October 6, 2026 report. Revenue exceeded the cited USD 16.80 billion estimate, while EPS beat the USD 3.61 consensus by USD 0.04.

Guidance adds a counterweight

MarketBeat also reported that AbbVie lowered third-quarter adjusted EPS guidance to USD 3.73-3.77 from the earlier USD 3.87-3.91 range. Full-year adjusted EPS guidance fell to USD 13.76-13.96 from USD 13.87-14.07 after the company included USD 216 million of acquired in-process research and development and milestone expenses.

The pipeline supplied a separate growth signal. In a company announcement carried by Genmab on October 5, 2026, epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51 percent in newly diagnosed diffuse large B-cell lymphoma. The combination remains investigational and still requires regulatory discussions.

Stock sits near yearly high

AbbVie was trading at USD 272.68 on October 7, 2026, only USD 0.05 below the session high of USD 272.73 and 0.02 percent below the 52-week high. The 52-week range runs from USD 190.75 to USD 272.73, while market capitalization stands at USD 481.8 billion and volume at 627,606 shares.

The analyst backdrop is constructive but less aggressive than the price move. StockHub lists a Buy consensus based on 28 analyst targets, with a median target of USD 285.00 and a range of USD 200.00 to USD 328.00. The October earnings release therefore matters more than the headline trial result for the next valuation step.

Upcoming dates shape the setup

AbbVie declared a quarterly dividend of USD 1.73 per share, with October 15, 2026, listed as the ex-dividend date and November 16, 2026, as the payment date, according to MarketBeat. The combination of a near-high share price, reduced EPS guidance and a fresh oncology result leaves the October report as the central measure of execution.